Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding of the industry's evolution and the pivotal roles he played at Theravance, Merck, and J&J. The episode delves into the significance of intracellular protein interactions and FogPharma's focus on developing helicon peptides to address this unmet n ..read more

Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior experience, led to his pivotal role in establishing a successful biotech company in Canada, shaping the industry significantly. Throughout the conversation, he emphasizes the critical elements of leadership, continuous learning, and the relentless pursuit of groundbreaking science. Galbraith's focus ..read more

Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance and accounting background and pivotal roles in pharmaceutical companies like Bristol Myers Squibb and Alza Pharmaceuticals. His passion for impactful drug delivery technologies led to the launch of life-changing products, including an intranasal diazepam program for seizure emergencies, ultimately culminating in t ..read more

Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements. His insights into the gene therapy landscape and the future of genetic medicine, including its intersection with artificial intelligence, offer valuable perspectives for biotech professionals seeking to navigate the complexities of precision medicine and drug development. Tuyen's emphasis on fostering ..read more

Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in aging biology, genetics, and statistics underscores her expertise in the field. The conversation delves into the shift towards translational research in aging biology, emphasizing the increasing interest in targeting aging-related diseases such as heart disease, Alzheimer's, and cancer. Kristen highlights the importance of le ..read more

Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making biotech more accessible to a broader audience while maintaining the integrity of the science. He discusses the need for a broader investor community in biotech to unlock more capital and stimulate early-stage science funding. His unique perspective highlights the intersection of tech and biotech ..read more

Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution to create innovative treatments for genetic diseases. By utilizing directed evolution, 4D Molecular Therapeutics has been able to invent an AAV vector that achieves safe and effective gene expression in the retina, targeting rare genetic diseases initially and subsequently expanding to larger markets. Kirn emph ..read more

Synopsis: In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics, underscores his deep understanding of the industry. He offers a comprehensive analysis of the impact of the Inflation Reduction Act (IRA) on indication selection and the evolving capital market for biotech companies. The episode delves into the complexities of proving safety and tolerability in new mec ..read more

Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, shedding light on the capital-intensive nature of drug development. Furthermore, he highlights the value of experienced investors and the impact of their investment source, emphasizing the advantage of being one of the first investments out of a fund ..read more

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema since then, including an update on their lead product candidate. Sean reflects on navigating the challenging biotech market environment over the past year, making careful spending decisions, and raising significant capital to extend Olema’s runway. He al ..read more